Assessment of BCR-ABL1 transcript levels at 3 months is the major determinant for outcome in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

被引：0
|
作者：
Katalinic, D. [1 ]
机构：
[1] JJ Strossmayer Univ Osijek, Fac Med, Dept Internal Med, Zagreb, Croatia
来源：
EUROPEAN JOURNAL OF CANCER | 2017年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
772
引用
收藏
页码：S100 / S100
页数：1
相关论文
共 50 条
  • [21] Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
    Takeuchi, Asako
    Kondo, Toshinori
    Tasaka, Taizo
    Yamada, Seiko
    Hirose, Tadashi
    Fukuda, Hirofumi
    Shimizu, Risa
    Matsuhashi, Yoshiko
    Kondo, Eisei
    Wada, Hideho
    LEUKEMIA RESEARCH REPORTS, 2021, 15
  • [22] Distribution of BCR-ABL1 Transcript Variants in Nigerians with Chronic Myeloid Leukemia
    Owojuyigbe, Temilola O.
    Durosinmi, Muheez A.
    Bolarinwa, Ramoni A. A.
    Salawu, Lateef
    Akinola, Norah O.
    Ademosun, Abdulwaheed A.
    Bosede, Oluwayomi T.
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2020, 36 (04) : 646 - 651
  • [23] Economic Burden of Adverse Events Among Patients with Chronic Myelogenous Leukemia Treated with BCR-ABL1 Tyrosine Kinase Inhibitors
    Lin, Jay
    Dinara, Makenbaeva
    Robyn, Bilmes
    Lingohr-Smith, Melissa
    Wallis, Nicola
    BLOOD, 2015, 126 (23)
  • [24] Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study
    Abu Seman, Zahidah
    Ahid, Fadly
    Kamaluddin, Nor Rizan
    Sahid, Ermi Neiza Mohd
    Esa, Ezalia
    Said, Siti Shahrum Muhamed
    Azman, Norazlina
    Mat, Wan Khairull Dhalila Wan
    Abdullah, Julia
    Ali, Nurul Aqilah
    Khalid, Mohd Khairul Nizam Mohd
    Yusoff, Yuslina Mat
    BMC RESEARCH NOTES, 2024, 17 (01)
  • [25] BCR-ABL1 RT-qPCR for Monitoring the Molecular Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
    Press, Richard D.
    Kamel-Reid, Suzanne
    Ang, Daphne
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (05): : 565 - 576
  • [26] Comment on "Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors"
    Kim, Sung-Hyun
    Kim, Dong-Wook
    HAEMATOLOGICA, 2015, 100 (03) : E120 - E121
  • [27] Impact of Simultaneous Presence of Additional Chromosome Aberrations and BCR-ABL1 Kinase Domain Mutations on Survival in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
    Fominykh, Mikhail
    Shuvaev, Vasily
    Martynkevich, Irina
    Shukhov, Oleg
    Chelysheva, Ekaterina
    Turkina, Anna G.
    Abdulkadyrov, Kudrat
    BLOOD, 2016, 128 (22)
  • [28] Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
    Dakota Gustafson
    Jason E. Fish
    Jeffrey H. Lipton
    Nazanin Aghel
    Current Hematologic Malignancy Reports, 2020, 15 : 20 - 30
  • [29] MOLECULAR RESPONSE TO THERAPY WITH TYROSINE KINASE INHIBITORS IN PATIENTS WITH BCR-ABL1(+) CHRONIC MYELOID LEUKEMIA PRESENTING WITH AN ISOLATED THROMBOCYTOSIS AT THE ONSET
    Balatzenko, G.
    Hrischev, V.
    Ignatova, K.
    Stoyanova, Z.
    Lilova, A.
    Angelova, S.
    Ivanova, S.
    Romanova, M.
    Ivanova, I.
    Tsvetkova, G.
    Hadjiev, E.
    Madzharova, V.
    Dikov, T.
    Spassov, B.
    Davidkova, Y.
    Jagurinoski, M.
    Guenova, M.
    HAEMATOLOGICA, 2017, 102 : 733 - 733
  • [30] Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
    Gustafson, Dakota
    Fish, Jason E.
    Lipton, Jeffrey H.
    Aghel, Nazanin
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2020, 15 (01) : 20 - 30
12345